Big pharmaceutical companies could face increased competition from generic drugmakers under two proposals put forth by the Obama administration on Monday despite earlier savings extracted from drugmakers as part of last year’s healthcare law. Read More
The Obama Administration’s fiscal 2012 budget document includes a call to reduce innovator biologics exclusivity from the 12 years just enacted as part of the health care reform law to 7 years, a number more in line with the position supported by advocates on the generic/drug/purchaser/consumer side of the debate. Read More
James Sykes, Director of Global Policy, The AIDS Institute The Hill Our nation’s political capital, Washington D.C. also has the notorious distinction of being the HIV and AIDS capital of the United States, with at least 3 percent of its residents infected. This rate is higher than most countries in West Africa and exceeds the […]
Marcia Boyle, President and Founder, Immune Deficiency Foundation AOL News Thirty years ago my infant son was diagnosed with a rare genetic disorder that make even common cold germs potentially life threatening. His disorder — clinically termed a primary immunodeficiency disease — started me on my career as a patient activist. Read More
Where there’s medicine, there’s money.
Biologic drugs can treat a variety of illnesses—including cancer and certain types of arthritis—imore effectively than traditional, chemical based products.
Biologic drugs are often referred to as ”miracle drugs“ for good reason…
Americans elected a new Congress on Nov. 2, but the voting booth wasn’t the only place where critical issues were at stake that day.
Away from the spotlight of election news coverage, a committee of the U.S. Food and Drug Administration (FDA) held a hearing in a Washington suburb on the future of biologic drugs…
For cancer patients, what is the “acceptable risk” that a drug will pose safety risks or won’t work properly?